CAI Caris Life Sciences, Inc.

NASDAQ
$26.05

Caris Life Sciences, Inc. (CAI) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

30D 90D 6M 1Y
Insider signal In line Selling ran in line with CAI's own trailing one-year pace, with 10% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 1 seller in the last 90 days
Insiders buying
4
4 transactions
Insiders selling
2
5 transactions
Purchases
$1.6M
103,634 shares
Sales
$16.5M
659,462 shares
Net activity
-$14.9M
purchases less sales

How much of that selling was preplanned? 10% planned / 90% discretionary

10b5-1 plan sales $1.7M 2 transactions · 62,250 shares
Discretionary sales $14.8M 3 transactions · 597,212 shares

Largest single sale: $9.7M.

Where they traded

Buy Sell Dot area is proportional to transaction value.

Last open-market purchase: May 15, 2026 , by HALBERT JON .

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Spetzler David Baxley President Sell 119,212 $24.76 $3.0M 1,182,871 −9.2% of holding
Spetzler David Baxley 2 fills President Sell 478,000 $24.86 $11.9M 1,136,983 −29.6% of holding
HALBERT JON Director Buy 68,000 $14.56 $990.1K 704,598
Vacirca Jeff L Director Buy 31,050 $16.15 $501.4K 49,671
Power Luke Thomas 2 fills See Remarks Sell 10b5-1 62,250 $26.58 $1.7M 100,971 −38.1% of holding
Denton John Russel See Remarks Buy 4,184 $24.09 $100.8K 9,184
Spetzler David Baxley President Buy 400 $23.85 $9.5K 460,777

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.